RECURSION PHARMACEUTICALS, INC. — Form 8-K
Filed September 21, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 32/100
What the filing says
Recursion Pharmaceuticals filed an 8-K on 2026-09-21 reporting entry into a material definitive agreement (Item 1.01) as of 2026-09-15. The filing header provides no counterparty name, dollar amounts, percentages, share counts, or description of the agreement's terms or business purpose. Full details would be in the attached exhibits, which are not provided in this text excerpt.
Why this rating
Cannot assess significance without knowing deal terms, size, or counterparty. Material agreement is routine disclosure; impact depends entirely on missing details.
Extracted items
See more from September 21, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.